A strong association between inflammatory cytokines and capillary abnormalities is suggested by the reported efficacy of brodalumab, an anti-IL-17RA antibody, in the treatment of systemic sclerosis, one of the most common diseases showing nailfold capillary abnormalities (29–31). This evidence concerns the gene IL17RA and systemic sclerosis.